Tag: Cancer Drugs

Adaptive and Genentech to Develop Treatment of Cancers

Adaptive Biotechnologies, an immune-driven medicine company, today announced that it will enter into a worldwide collaboration and license agreement with Genentech, a member of the Roche Group, to dev...

BioNTech and Sanofi to Co-develop Cancer Immunotherapy

French multinational pharmaceutical company Sanofi investing €80m in equity in BioNTech, which is claimed to be the Europe’s largest privately-held biopharmaceutical firm focused on the development of...

Takeda to Develop Novel CAR-T Products

Takeda is upping its commitment to cancer after its Shire takeover with the announcement of three new research collaborations in immuno-oncology. In the first deal, Takeda will collaborate with Mem...

Samumed’s Pancreatic Cancer Drug Granted ODD

Samumed, LLC announced that the U.S. Food and Drug Administration granted orphan drug designation (ODD) for SM08502 for the treatment of pancreatic cancer. A phase 1, open‐label, multicenter, dose es...

Jazz Pharmaceuticals and Codiak to R&D Cancer Treatment

Jazz Pharmaceuticals plc and Codiak BioSciences, Inc. announced that the companies have entered into a strategic collaboration agreement focused on the research, development and commercialization of e...

AbbVie and Tizona to Develop Antibody for Cancer Treatment

AbbVie, a research-based global biopharmaceutical company, and Tizona Therapeutics, Inc., a privately held immunotherapy company, announced on Jan. 3, 2019 that they have entered into a global, strate...

Almac Brings Online Second GMP Peptide Facility

Based in Edinburgh, Scotland, the facility manufactures neoantigen derived peptides for use in the production of patient specific, individualised cancer vaccines Almac Group has brought online a se...

Chinese Pharma Collaboraton for Cancer Drug Development

InventisBio announced that it has signed a "Collaboration Agreement" with Betta Pharma. Under this agreement, InventisBio will out-license D-0316's right in China (including mainland China, Hong Kong ...

First Patient Dosed in First-Line Treatment of Advanced Cancer

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines, announced that the first patient has been dosed in a phase III clinical trial...

Xynomic Files 3 IND Applications to Test Abexinostat

Xynomic Pharma, a clinical stage US-China oncology drug development company, today announced that its Trials-in-Progress poster discussing the ongoing, potentially pivotal, phase 3 trial of abexinosta...

Vedanta Raised $27m to Investigate Microbiome-Derived Therapies

US-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several indications, including cancer and food allergy. Investors include...

Merck and Pfizer’s Cancer Drug Failed Second Trial

Merck KGaA and Pfizer PD-L1 inhibitor Bavencio has missed the mark in its second ovarian cancer trial in a month, this time failing in previously-untreated patients. Results from a planned interim ...

Berlin Chemie obtained licensing rights to investigational cancer drug

lab-tests
Helsinn and Menarini announced that Berlin Chemie, the German company of the Menarini Group, has been granted rights to commercialize Pracinostat.

Personalized medicine will have the biggest impact on pharma industry in 2019

stem-cell
According to the report, ‘The State of the Biopharmaceutical Industry - 2019’, 31% of global industry respondents believe that immuno-oncology will have the greatest impact on the pharma sector.

Xynomic to Acquire Phase II-Ready Cancer Treatment

Xynomic Pharmaceuticals, a pharma company with roots in both the U.S. and China, forged a deal worth up to $800 million to acquire a Phase II-ready cancer treatment from Germany-based Boehringer Ingel...

FDA Pushes Back Decision Date for Keytruda Review

US regulators have pushed back the deadline for their review of Merck & Co’s immunotherapy Keytruda in certain patients with untreated lung cancer, after the pharmaceutical company submitted new d...